Related Experiment Videos
Mucosal ablation in Barrett's esophagus.
S J Walker1, C R Selvasekar, N Birbeck
1Blackpool Victoria Hospital NHS Trust, Blackpool, UK. stevenjwalker@ntlworld.com
Summary
Ablation therapy can remove Barrett's esophagus (BE) in about one-third of patients, with partial response in most others. Antireflux therapy is crucial for maintaining results, but long-term cancer risk reduction requires further study.
Area of Science:
- Gastroenterology
- Oncology
- Gastroesophageal Reflux Disease
Background:
- Barrett's esophagus (BE) is a common premalignant condition of the esophagus.
- Adenocarcinoma is a potential complication of BE.
- Esophagectomy is a treatment option for BE, but not suitable for all patients.
Purpose of the Study:
- To review the current literature on ablation therapy combined with antireflux treatment for Barrett's esophagus.
- To evaluate the efficacy and safety of various ablation techniques.
- To assess the role of this combined therapy in preventing esophageal adenocarcinoma.
Main Methods:
- Literature search of Medline/ISI databases and cross-referencing.
- Review of studies on ablation techniques including laser, electrocoagulation, argon plasma coagulation, and photodynamic therapy.
- Analysis of outcomes related to mucosa removal and patient response.
Main Results:
- Ablation techniques vary, with no single method proving superior.
- Complete removal of Barrett's esophagus is achieved in approximately one-third of patients; partial response in nearly two-thirds.
- Antireflux therapy is essential for maintaining regenerated squamous mucosa and preventing recurrence.
Conclusions:
- Ablation plus antireflux therapy is a viable option for managing Barrett's esophagus, particularly for patients unable to undergo esophagectomy.
- Long-term data is needed to definitively establish the impact on cancer risk.
- Regular endoscopic surveillance remains necessary following treatment.